Giving blood: a new role for CD40 in tumorigenesis
Open Access
- 16 October 2006
- journal article
- editorial
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 203 (11) , 2409-2412
Abstract
CD40 was initially identified as a receptor expressed by B cells that is crucial for inducing an effective adaptive immune response. CD40 was subsequently shown to be expressed by endothelial cells and to promote angiogenesis. New data now show that in tumor-prone transgenic mice, CD40-mediated neovascularization is essential for early stage tumorigenicity. This suggests, at least in this mouse model, that CD40 has an important role in the angiogenic process that is coupled to carcinogenesis, a finding that could lead to novel therapeutic opportunities.Keywords
This publication has 33 references indexed in Scilit:
- Triggering CD40 on endothelial cells contributes to tumor growthJournal of Experimental Medicine, 2006
- Biology of vascular endothelial growth factorsFEBS Letters, 2006
- Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and MetastasisCell, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesisOncogene, 2005
- CD36:A Multiligand MoleculeLaboratory Hematology, 2005
- The Hallmarks of CancerCell, 2000
- Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in MiceScience, 1999
- CD40 AND CD154 IN CELL-MEDIATED IMMUNITYAnnual Review of Immunology, 1998
- A central role of CD40 ligand in the regulation of CD4+ T-cell responsesImmunology Today, 1996